Navigation

ExploreAnalysisInvestor RelationsAI AssistantCompareScreener
LoginSign Up FreeSign Up

© 2026 MarketCI. All rights reserved.

HelpPricingPrivacyTerms
AR

ARWR

Market Closed

Arrowhead Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnology
US
711 employees
CEO: Christopher R. Anzalone
Founded: 1993
$86.34
+$0.00(+NaN%)
Market Cap
12.16B
Beta
1.28
52W Range
N/A
Dividend Yield
0.00%
OverviewForecastsFundamentalMarket SentimentValuationOwnership
OverviewForecastsFundamentalMarket SentimentValuationOwnership
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Based on PERT weighted analysis (confidence: high), the fair value is $33.11, implying 61.7% downside from current levels. The stock appears significantly overvalued. Financial health scores indicate weak fundamentals (1.8/5). Monte Carlo analysis shows low downside risk (0% of scenarios below current price). Overall, this suggests a elevated valuation risk at current prices.
Enhanced Football Field Analysis
Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore ARWR

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

ARWR in the Healthcare

Large Cap
Healthcare

Browse sector stocks →

Biotechnology

Browse industry stocks →